What is BPC-157?
BPC-157 — short for Body Protection Compound-157 — is a synthetic peptide of 15 amino acids, which is why chemists call it a pentadecapeptide. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a partial fragment of a larger protective protein originally isolated from human gastric juice. Most of the published work originates from the laboratory of Professor Predrag Sikiric at the University of Zagreb, who has authored the bulk of the more than 100 peer-reviewed preclinical studies on the molecule.
The first thing that sets BPC-157 apart from almost every other research peptide is stability. Where peptides typically denature quickly in acid, BPC-157 has been shown to remain stable in human gastric juice for over 24 hours in vitro. That robustness is why both oral and injectable routes appear across the literature, and it is part of why the compound became a workhorse for cytoprotection research.
How BPC-157 works: four reported mechanisms
The reason researchers find BPC-157 interesting is that it does not appear to act through a single receptor. Instead, the literature describes several overlapping pathways that converge on tissue repair. The table below summarises what is reported in animal and cell-culture models — not in humans.
| Pathway | What happens | Reported relevance to repair |
|---|---|---|
| Angiogenesis | Upregulation of VEGFR2 signalling and new capillary formation | Greater oxygen and nutrient delivery to damaged tissue |
| Nitric-oxide modulation | Interaction with the NO system and vasodilation | Improved local blood flow in injury models |
| Growth-factor signalling | Influence on EGF, FGF and the FAK-paxillin pathway | Stimulation of fibroblast and tendon-cell outgrowth |
| Cytoprotection | Stabilisation of the gut and endothelial lining | Resistance to NSAID-, stress- and alcohol-induced damage |
The VEGFR2 angiogenesis pathway is the one most often cited as the unifying mechanism: a 2014 study in the Journal of Applied Physiology (Chang et al.) reported that BPC-157 promoted the outgrowth of tendon fibroblasts and that blocking VEGFR2 abolished the effect — pointing to vascular signalling as central to the repair phenotype.
What the BPC-157 research evidence shows
Two research domains dominate the BPC-157 literature: musculoskeletal repair (tendon, ligament, muscle) and gastrointestinal protection. A third, smaller body of work covers nerve and skin healing.
Tendon and ligament models
In a transected Achilles-tendon rat model, Krivic et al. (2006, Journal of Orthopaedic Research) reported accelerated functional recovery in BPC-157-treated animals. Cerovecki et al. (2010) reported faster healing of a transected medial collateral ligament. These are the studies most often quoted in the context of joint and connective-tissue research — but, again, they are animal experiments.
Gastrointestinal protection
Because of its gastric origin, BPC-157 has been studied extensively as a gut-protective agent. Sikiric et al. (2018, Current Pharmaceutical Design) reviewed dozens of models in which BPC-157 limited ulceration and supported mucosal integrity against NSAIDs, alcohol and stress. This gut-protection signal is one of the more reproducible findings in the dataset.
Forms, purity and what to check when sourcing
BPC-157 is a short peptide, which makes it relatively easy to synthesise — and, unfortunately, relatively easy to sell in poorly purified batches. When evaluating research-grade material, the checklist below matters more than price.
- Purity ≥ 99% by HPLC, with a recent batch Certificate of Analysis from a named laboratory (e.g. Janoshik).
- Correct sequence and mass. Genuine BPC-157 has a monoisotopic mass near 1419 Da; mass-spectrometry on the COA confirms identity rather than a truncated analogue sold under the same name.
- Salt form stated. Acetate is the common research form; a credible supplier states it explicitly.
- Lyophilised, light-protected packaging sealed under inert gas — the powder should be white and intact.
For the wider framework on purity standards, storage and red flags across compounds, see the complete research peptides guide. The hands-on reconstitution and concentration math lives in the dedicated BPC-157 dosage and reconstitution guide.
BPC-157 and TB-500 in regeneration research
The most commonly studied pairing in this field is BPC-157 with TB-500, the synthetic fragment of Thymosin Beta-4. The rationale is mechanistic complementarity: BPC-157 acts locally and drives angiogenesis, while TB-500 acts systemically through actin regulation and cell migration. Our TB-500 research guide covers that compound in detail.